Brain-X（交叉脑科学）主要聚焦与脑/神经科学有交叉融合的多学科前沿！
本文转自“Wiley威立”
Citescore：4.4
SNIP (2021)：1.033
Journal Citation Indicator (JCI)：0.68
5 Year Impact Factor：3.101
Impact factor (2022):2.6
Journal Citation Reports (Clarivate, 2022): 192/279 (Pharmacology & Pharmacy)133/210 (Public, Environmental & Occupational Health)
Online ISSN:1099-1557
Evaluating the Impact of Regulatory Decisions using Real-World Evidence
Medicinal products are rigorously assessed by regulators before these are authorized for use in populations. As not all aspects of their safety is known at market approval, pharmacovigilance systems have been put in place to safeguard a positive benefit-risk balance during their lifecycle. When new safety concerns are discovered, regulators can implement risk minimization measures in order to maintain a positive benefit-risk balance. These measures usually aim to prevent or reduce the occurrence of adverse reactions with a medicine, or to reduce their severity or impact on patients, through changes in the knowledge and behavior of individuals (e.g. patients, consumers, caregivers and healthcare professionals) and in healthcare practice.
An important step in continuous monitoring of medicines safety is assessing the impact of these risk minimization interventions, those intended as well as unintended. Real-world data is frequently used to provide insights into how public health and regulatory policy interventions influence patient care. Pharmacoepidemiology and Drug Safety is therefore calling for papers for a special issue that will focus on use of real-world data to measure impact of regulatory decisions.
This special issue welcomes original papers (methods papers, frameworks, tutorials, and commentaries) focused on “how-to” to use real world data for measuring impact of regulatory interventions. This issue calls for original scientific and technical contributions.
-
Measuring the targeted impact of regulatory interventions
-
Measuring the unintended impact of regulatory interventions
-
Methodologies for measuring the impact of regulatory interventions
-
Tutorials related to measuring the impact of regulatory interventions
Helga Gardarsdottir
Utrecht University
Netherlands
Daniel Morales
European Medicines Agency
Netherlands
During submission, please select “Evaluating the Impact of Regulatory Decisions using Real-World Evidence” at the Special Issue custom question found in the Additional Information section during submission to ensure that your submission is considered for the appropriate special issue.
Pharmacoepidemiology and Drug Safety的CAR指数
2023年3月份科睿唯安官方一次性踢除35本SCI期刊，多数涉及学术诚信问题，让我们意识到学术期刊的“被踢”指数，也很重要。目前，对于期刊的
“被踢”指数
，这里介绍一下：
CAR指数
（关于C
AR的
详
细介绍，请关注：
www.jcarindex.com
）
，这是一种评价期刊学术诚信风险的指数，
指数
越高代表可能的风险越大。从数据看，
Pharmacoepidemiology and Drug Safety
不管是2022年度，还是2023年度实时的CAR指数，都是比较低的。
当然，
CAR指数仅供参考，期刊风险情况，需以科睿唯安或中科院预警等官方为准！
